Hypertriglyceridemia and pancreatitis associated with estramustine phosphate.
Estramustine phosphate is associated with estrogenic complications. However, hypertriglyceridemia has not yet been associated with estramustine phosphate. We describe a patient in whom severe hypertriglyceridemia and pancreatitis developed after treatment with estramustine phosphate. A 59-year-old man with hormone-refractory prostate cancer was treated with estramustine phosphate, docetaxel, and carboplatin. After three cycles, the patient was admitted with triglyceride levels of 12,210 mg/dl and pancreatitis. After resolution of hypertriglyceridemia and pancreatitis, chemotherapy with docetaxel and carboplatin was continued without recurrence of hypertriglyceridemia. We conclude that estramustine phosphate has the potential to cause hypertriglyceridemia in susceptible individuals.
Olson
Eric L
EL
Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, U.S.A.
Whang
Young E
YE
D000970:Antineoplastic Agents / Q000009:adverse effects*; D004961:Estramustine / Q000009:adverse effects*; D006801:Humans; D015228:Hypertriglyceridemia / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D010195:Pancreatitis / Q000139:chemically induced*; D011471:Prostatic Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents; D004961:Estramustine